Delving into the Latest Updates on Haupt Pharma Wülfing GmbH with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

QPCT(Glutaminyl-peptide cyclotransferase)	1

主要目的：剂量选择的安全性 ● 评估PQ912的安全性和耐受性疗效 ● 评价PQ912对工作记忆和注意力的作用次要目的安全性 ● 评估PQ912的长期安全性和耐受性疗效 ● 评价PQ912对脑活动 (EEG) 的作用 ● 评价PQ912对认知的作用 ● 评价PQ912对日常生活能力的作用

[Translation]

Primary objectives: Safety of dose selection ● Evaluate the safety and tolerability of PQ912 Efficacy ● Evaluate the effect of PQ912 on working memory and attention Secondary objectives Safety ● Evaluate the long-term safety and tolerability of PQ912 Efficacy ● Evaluate the effect of PQ912 on brain activity (EEG) ● Evaluate the effect of PQ912 on cognition ● Evaluate the effect of PQ912 on daily living ability

Start Date-

Sponsor / Collaborator

Jiangsu Simcere Pharmaceutical Co., Ltd.

[+2]

NCT01069965 / TerminatedPhase 2

Randomized, Double-blind, Placebo-controlled, Parallel Group, Multiple Dose, Multicenter Study to Assess Safety & Efficacy of BGP-15 Administered Orally 1 or 2 Times Daily With Metformin & Sulfonylurea or Metformin in T2 Diabetic Patients

This is a safety and dose finding efficacy study to evaluate the effects of BGP-15 over the dose range of 100 mg/day to 400 mg/day. Doses are applied once or twice a day for 13 weeks as add-on therapy to the combination of metformin and sulfonylurea treatment or metformin alone in patients with Type 2 Diabetes Mellitus.

Start Date01 Oct 2010

Sponsor / Collaborator

N-Gene Research Laboratories, Inc.

[+6]

100 Clinical Results associated with Haupt Pharma Wülfing GmbH

Login to view more data

0 Patents (Medical) associated with Haupt Pharma Wülfing GmbH

Login to view more data

100 Deals associated with Haupt Pharma Wülfing GmbH

Login to view more data

100 Translational Medicine associated with Haupt Pharma Wülfing GmbH

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data